510(k) device
MagVita TMS Therapy w/MagPro R20
Tonica Elektronik A/S · Transcranial Magnetic Stimulator (OBP, Class II) · First FDA decision Jul 31, 2015, newest Oct 5, 2017DepressionOCD, PTSD and other psychiatric conditions
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
510(k) pathway
Device trials
2
Naming "MagVita TMS Therapy"
MAUDE reports
1
Brand "MagVita TMS Therapy", since 2015
PubMed studies
0
Mentioning "MagVita TMS Therapy"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing MagVita TMS Therapy w/MagPro R20
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
K172667 · Decided Oct 5, 2017 · 30 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K171967 · Decided Jul 25, 2017 · 25 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
K171481 · Decided Jun 16, 2017 · 28 days after receipt
Device type: Transcranial Magnetic Stimulator (OBP) · Neurology & Neurosurgery
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcranial Magnetic StimulationLocal determinationIn effectL33398Wellpoint FederalUpdated Jul 16, 2026
- Transcranial Magnetic StimulationProposed local determinationProposedDL33398National Government Services, Inc.Updated Mar 27, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL34641WPS Insurance CorporationUpdated Mar 20, 2026
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL37086Noridian Healthcare Solutions, LLCUpdated Aug 6, 2025
- Repetitive Transcranial Magnetic Stimulation (rTMS) in AdultsLocal determinationIn effectL34869Palmetto GBAUpdated Jan 7, 2025
- Transcranial Magnetic Stimulation (TMS)Local determinationIn effectL36469CGS Administrators, LLCUpdated May 30, 2024
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34522First Coast Service Options, Inc.Updated Oct 21, 2022
- Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive DisorderLocal determinationIn effectL34998Novitas Solutions, Inc.Updated Oct 21, 2022
Clinical trials
Device studies on ClinicalTrials.gov that name "MagVita TMS Therapy", any status and sponsor, newest update first.
- Using rTMS to Treat DepressionActive, not recruiting
Florida International UniversityAcademic, hospital or other
NCT05424224 · 30 participants (planned) · Start Jan 9, 2023 · Primary completion Sep 1, 2027
Device: MagVita · For: Depression
Sites: Miami, Florida
- rTMS Response Trajectories in DepressionRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT03348761 · 70 participants (planned) · Start Aug 4, 2015 · Primary completion Dec 2026
Device: rTMS group · For: Depression
Sites: Hong Kong, Hong Kong
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "MagVita TMS Therapy", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code OBP
337 reports: 9 malfunction, 323 injury, 2 death
Newest reports for this brand
MAGVENTURE A/S / TONICA ELEKTRONIC A/S
MW5098553 · Received Dec 28, 2020 · Event dated Dec 14, 2020
Device type: Transcranial Magnetic Stimulator (OBP)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Emotional Changes; Fatigue; Headache; Hearing Loss; Memory Loss/Impairment; Pain; Tinnitus; Vomiting; Brain Injury; Sleep Dysfunction; Cognitive Changes; Weight Changes; Hyperresponsive to stimuli
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "MagVita TMS Therapy"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OBP.
- NeuroStar TMS Therapy SystemNeuronetics, Inc. · 510(k) 2022
- BrainsWay Deep TMS SystemBrainsway , Ltd. · 510(k) 2025
- Apollo TMS Therapy SystemMag & More GmbH · 510(k) 2026
- NeuroStar Advanced Therapy System (All previously cleared models)Neuronetics, Inc. · 510(k) 2024
- Magstim Horizon 3.0 TMS Therapy SystemMagstim Company, Ltd. · 510(k) 2023
- HORIZON TMS Therapy System with NavigationMagstim Company, Ltd. · 510(k) 2019
- Nexstim Navigated Brain Stimulation (NBS) 6 System (NBS6)Nexstim Oyj · 510(k) 2026
- MagVenture TMS Therapy SystemTonica Elektronik A/S · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.